Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Pancreatic Neoplasms 3Neoplasms 3Carcinoma, Hepatocellular 3Neoplasm Metastasis 2Glioma 2Glioblastoma 2Triple Negative Breast Neoplasms 1Solid Tumor 1Carcinosarcoma 1Camurati-Engelmann Syndrome 1Breast Neoplasms 1

Interventions

Temozolomide 88Bevacizumab 49Radiotherapy 36Irinotecan 22Magnetic Resonance Spectroscopy 20Surgical Procedures, Operative 17Carboplatin 17Carmustine 15Radiation 13Nivolumab 11IL13-PE38 8Erlotinib Hydrochloride 8Thalidomide 7Radiotherapy, Intensity-Modulated 7Lomustine 7Imatinib Mesylate 7Everolimus 7Aminolevulinic Acid 7sargramostim 6Topotecan 6O(6)-benzylguanine 6Cyclophosphamide 6Chemotherapy, Adjuvant 6vandetanib 5temsirolimus 5fluorodopa F 18 5Vincristine 5Surveys and Questionnaires 5Radiosurgery 5Flucytosine 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Glioma × LY-2157299 × Clear all
NCT01682187 2024-11-07

A Dose-Escalation Study in Participants With Recurrent Malignant Glioma

Eli Lilly and Company

Phase 1 Completed
66 enrolled
CNS

Glioma

NCT01220271 2017-02-16

A Study Combining LY2157299 With Temozolomide-based Radiochemotherapy in Patients With Newly Diagnosed Malignant Glioma

Eli Lilly and Company

Phase 1/2 Completed
75 enrolled
CNS

Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡